SEC Form 4 · accession 0001415889-18-000591
INNOVUS PHARMACEUTICALS, INC. · INNV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Randy Berholtz
Officer — EVP, CORPORATE DEVELOPMENT
Period of report
Apr 5, 2018
Accepted (ET)
Apr 6, 2018 · 4:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411879
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Apr 5, 2018 | A | 1,000,000 | A | — | Apr 5, 2028 | Common Stock | 1,000,000 | 3,675,000 | D |
Explanation of responses
- F1Each restricted stock unit represents the contingent right to receive, at settlement, one share of common stock.
- F2RSU was granted on April 5, 2018. The RSUs vest in two separate tranches of 500,000 upon the achievement of certain company milestones, subject to continued service through the achievement of the milestones.
- F3These restricted stock units were granted pursuant to the Issuer's Amended and Restated 2016 Equity Incentive Plan.